Based on drug class, the plasma protease C1-inhibitor treatment industry is classified as C1-inhibitors, kallikrein
inhibitor (kalbitor), selective bradykinin B2 receptor antagonist (firazyr) and so on. The segment “C1-inhibitor” is sub-
divided into C1-esterase inhibitor, recombinant inhibitor, and so on. The segment “lyophilized” held highest share in
the past few years due to rising practice of intravenous administration of drugs for the treatment of HAE.
Get a Sample Copy of This Report @
https://www.millioninsights.com/industry-reports/plasma-protease-c1-inhibitor-treatment-market/request-sample
Based on distribution channel, the plasma protease C1-inhibitor treatment industry is classified as hospital pharmacies,
independent pharmacies & outlets, and so on. Based on geography, the plasma protease C1-inhibitor treatment
industry is classified as North America (U.S., Canada), Latin America (Brazil, Argentina, and Rest of Latin America),
Europe (EU-5 Countries, BENELUX countries, Rest of Europe), and Rest of World (Israel, Australia, Rest of world
countries).
See More Reports of This Category by Million Insights @
https://www.millioninsights.com/industry/healthcare
Market Segment:
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million
USD), market share and growth rate of Plasma Protease C1-inhibitor Treatment in these regions, from 2013 to 2025
(forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India